Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company collaborate with Odyssey Therapeutics, Inc. to designs and develops AI based discovery platform to discover new treatments in autoimmune and inflammatory diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.…
Evotec shares rise after second IND acceptance with Bristol Myers
Evotec (NASDAQ: EVO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 4,379 employees.
The shares were at 1.320 USD on 20 November 2026, down 58.0% over 52 weeks. Its 52-week range is 1.320 USD to 3.870 USD, and it trades at the bottom of that range.
Its market capitalisation is 469.11M USD.
Evotec reports return on equity of -12.7%, an operating margin of -18.0% and revenue up 0.6% year over year.
Its debt exceeds its cash by 80.88M EUR, a debt-to-equity ratio of 0.55. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 3 analysts cover the stock, with an average rating of Buy; their mean price target of 4.457 USD is 237.6% above the current price. The next earnings report is expected on 7 April 2027.